STOCK TITAN
  1. Home
  2. News
  3. BXRX

Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

MALVERN, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 1:15 p.m. ET.

A live webcast of the fireside chat will be available on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.

CONTACTS:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com


Stock BXRX logo
Baudax Bio, Inc.

OTC:BXRX

BXRX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BXRX Latest News

Oct 18, 2023
Baudax Bio Announces Corporate Update
Sep 28, 2023
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
Sep 7, 2023
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
Aug 23, 2023
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Aug 17, 2023
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

BXRX Stock Data

950.33k
43.59M
0.02%
2.68%
3.9%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Malvern

About BXRX

baudax bio, inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed phase iii clinical trials for the management of moderate to severe pain; and is in the phase iiib clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. the company's early-stage product candidates includes rp1000, an intermediate-acting neuromuscular blocking agent (nmba) that is in phase i clinical trial; and rp2000, an ultrashort-acting nmba, which is in pre-clinical trial; and a reversal agent, as well as dex-in, a proprietary intranasal formulation of dexmedetomidine. the company was incorporated in 2019 and is based in malvern, pennsylvania.